Von Eschenbach to resign from National Cancer Institute post

FDA acting commissioner Andrew von Eschenbach said this week he would resign from his other job, as director of the National Cancer Institute (NCI), effective June 10. Von Eschenbach’s holding of both positions had raised questions of a potential conflict of interest. He has led NCI since 2002. Von Eschenbach became acting commissioner in September 2005 and in March was nominated by President Bush to lead the regulatory agency. His confirmation remains “in limbo” amid debate on the FDA’s position on the OTC status of Barr’s emergency contraceptive pill Plan B.
You must be a registered member of MMM to post a comment.

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.